- Report
- February 2021
- 125 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- October 2023
- 172 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- March 2021
- 130 Pages
Global
From €13647EUR$14,995USD£11,699GBP
- Report
- June 2021
- 195 Pages
Global
From €3276EUR$3,600USD£2,809GBP
- Report
- June 2022
- 102 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- July 2024
- 107 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- October 2023
- 89 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- May 2023
- 86 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- November 2022
- 99 Pages
Global
From €1820EUR$2,000USD£1,560GBP
Erythropoietin is a hormone produced by the kidneys and liver that stimulates the production of red blood cells. It is used to treat anemia caused by kidney and liver disorders, such as chronic kidney disease and end-stage renal disease. It is also used to treat anemia caused by chemotherapy and other cancer treatments. Erythropoietin is available in both injectable and oral forms, and is often prescribed in combination with other drugs.
Erythropoietin is a widely used drug in the treatment of anemia caused by kidney and liver disorders. It is used to increase the production of red blood cells, which can help improve the patient's quality of life. It is also used to reduce the need for blood transfusions, which can be costly and time-consuming.
Several companies are involved in the production and distribution of erythropoietin. These include Amgen, Biogen, Johnson & Johnson, Novartis, Pfizer, and Roche. These companies produce and market erythropoietin under various brand names, such as Epogen, Procrit, and Aranesp. Show Less Read more